Skip Navigation

Cardiovascular Research 2000 45(2):447-453; doi:10.1016/S0008-6363(99)00345-4
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Osterziel, K. J.
Right arrow Articles by Böger, R. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osterziel, K. J.
Right arrow Articles by Böger, R. H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy

Karl Josef Osterziela,*, Stefanie M Bode-Bögerc, Oliver Strohma, Annette E Ellmera, Nana Bit-Avragima, Dankward Hänleina, Michael B Rankeb, Rainer Dietza and Rainer H Bögerc

aCharité/Franz-Volhard-Klinik, Humboldt Universität Berlin, Berlin, Germany
bKinderklinik der Universität Tübingen, Tübingen, Germany
cKlinische Pharmakologie, Medizinische Hochschule Hannover, Hannover, Germany

* Corresponding author. Tel.: +30-94-17-2221; fax: +30-94-17-2279 osterziel{at}fvk-berlin.de

Objective: Dilated cardiomyopathy is characterized by elevated arterial vascular resistance and impaired nitric oxide (NO)-dependent vasodilation. Insulin-like growth factor-I (IGF-I) has been shown to stimulate endothelial NO-synthase resulting in endothelium-dependent vasodilation. Growth hormone (GH) substitution therapy leads in GH-deficient patients to significant increases of IGF-I which may alter systemic vascular resistance by stimulating NO production. This study was designed to evaluate the effects of treatment with recombinant human growth hormone (GH) on NO production and NO-dependent vascular effects in patients with dilated cardiomyopathy. Methods: 50 patients with dilated cardiomyopathy were randomly assigned to double-blind treatment with 2 I.U. of GH or placebo for 3 months. Central hemodynamics were determined by Swan-Ganz catheter and cardiac output was obtained by the thermodilution method. Serum GH and IGF-I levels were measured and systemic NO production was determined from urinary nitrate and cyclic GMP excretion rates in 42 patients. Results: GH treatment caused in comparison to the placebo group a significant increase of IGF-I by 91 ng/ml (P=0.0001). Urinary excretion rates of nitrate and cyclic GMP increased also significantly by 38 µmol/mmol creatinine (P=0.027) and 65 nmol/mmol creatinine (P=0.003), respectively. The parallel increase of both marker molecules indicates increased systemic NO production during GH treatment. Conclusion: GH treatment induces a significant, but moderate increase of systemic NO production in patients with dilated cardiomyopathy. This effect may be mediated by IGF-I stimulating endothelial NO synthase.

KEYWORDS Cardiomyopathy; Endothelial factors; Growth factors; Hemodynamics; Nitric oxide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
G. Li, J.-P. del Rincon, L. A. Jahn, Y. Wu, B. Gaylinn, M. O. Thorner, and Z. Liu
Growth Hormone Exerts Acute Vascular Effects Independent of Systemic or Muscle Insulin-like Growth Factor I
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1379 - 1385.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.